ReviewESMO open2022
The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective.
Review in ESMO open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Trial
- Optimizing participation in digital health studies: understanding appointment attendance.Journal of the American Medical Informatics Association : JAMIA · 2026Article
- Mapping the evolution of immune checkpoint inhibitor research in small cell lung cancer: A bibliometric analysis (1997-2025).Human vaccines & immunotherapeutics · 2025Article
- Bringing Trial Activities to Participants-The Trials@Home RADIAL Proof-of-Concept Trial Investigating Decentralization of Trials.Clinical pharmacology and therapeutics · 2025Article
- Regulatory Interactions and Learnings-RADIAL the Trials@Home Proof-of-Concept Trial on Decentralization.Clinical pharmacology and therapeutics · 2025Article
- Article
- Telehealth in Gynecologic Oncology Clinical Trials: Qualitative Study of Patient, Researcher, and Clinician Perspectives.O&G open · 2024Article
- Viral Load Suppression in People Living with HIV Before and During the COVID-19 Pandemic in Brooklyn, New York.AIDS and behavior · 2024Article
- What Is Ailing Oncology Clinical Trials? Can We Fix Them?Current oncology (Toronto, Ont.) · 2024Review
- Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials.The oncologist · 2024Article
- Designing mHealth Apps to Incorporate Evidence-Based Techniques for Prolonging User Engagement.Interactive journal of medical research · 2024Article
- TBCRC 057: Survey about willingness to participate in cancer clinical trials during the pandemic.Cancer medicine · 2024Article
- Narrative review of telemedicine applications in decentralized research.Journal of clinical and translational science · 2024Review
- Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic.JCO oncology practice · 2023Article
- Review
- Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations.JNCI cancer spectrum · 2023Article
- First experience of a fully decentralized clinical trial: The dawn of a new era in oncology.Cancer science · 2023Article
- What went right during the COVID crisis: The capabilities of local actors and lasting innovations in oncology care and research.PLOS global public health · 2023Article
- Clinical trial reform in the post-COVID era.Therapeutic advances in medical oncology · 2023Review
- A nationwide pilot study on breast cancer screening in Peru.Ecancermedicalscience · 2023Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 13 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease-19 (COVID-19) pandemic promises to have lasting impacts on cancer clinical trials that could lead to faster patient access to new treatments. In this article, an international panel of oncology experts discusses the lasting impacts of the pandemic on oncology clinical trials and proposes solutions for clinical trial stakeholders, with the support of recent data on worldwide clinical trials collected by IQVIA. These lasting impacts and proposed solutions encompass three topic areas. Firstly, acceleration and implementation of new operational approaches to oncology trials with patient-centric, fully decentralized virtual approaches that include remote assessments via telemedicine and remote devices. Geographical differences in the uptake of remote technology, including telemedicine, are discussed in the article, focusing on the impact of the local adoption of new operational approaches. Secondly, innovative clinical trials. The pandemic has highlighted the need for new trial designs that accelerate research and limit risks and burden for patients while driving optimization of clinical trial objectives and endpoints, while testing is being minimized. Areas of considerations for clinical trial stakeholders are discussed in detail. In addition, the COVID-19 pandemic has exposed the underrepresentation of minority groups in clinical trials; the approach for oncology clinical trials to improve generalizability of efficacy and outcomes data is discussed. Thirdly, a new problem-focused collaborative framework between oncology trial stakeholders, including decision makers, to leverage and further accelerate the innovative approaches in clinical research developed during the COVID-19 pandemic. This could shorten timelines for patient access to new treatments by addressing the cultural and technological barriers to adopting new operational approaches and innovative clinical trials. The role of the different stakeholders is described, with the aim of making COVID-19 a catalyst for positive change in oncology clinical research and eventually in cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.